Tagged with IoT

China The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.   Canada scraps COVID-19 vaccine trial with Chinese CanSinoBIO https://globalnews.ca/news/7302041/canada-china-covid-19-vaccine-trials-abandoned-national-research-council/ Canada has decided to cancel a coronavirus vaccine development agreement…

China Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist approach to teambuilding helps it stand out from the crowd in China. He also touches on commercialization, partnerships, funding, and the evolution of the Chinese biopharma landscape.  …

China Founded in 2009 by CEO Dr XU Ting, Alphamab started its journey as a protein engineering company with the ultimate dream of becoming, as many Chinese biotechs aspire, a global biotech company producing world-class innovations. To learn more about some of China’s most innovative and inspirational biotech stories, download our…

Roundup A roundup of the latest news from Chinese pharma, including Big Pharma players losing out in the latest round of domestic procurement bidding, updates on Sinopharm’s experimental COVID-19 vaccine, biotech funding news, and Bayer and Hua Medicine’s diabetes collaboration.   Eli Lilly, Pfizer, Merck among Big Pharma losers in China’s…

China The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced since its establishment in 2017 at a pace that would seem to outpace the fast-moving China biotech industry.   [Post-merger], I-Mab became an…

China Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines his strategy for the company moving forward.   We believe, to make a meaningful impact on treatment, it is necessary…

Hong Kong It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain criteria. In May 2020, during the first in a series of webinars organized by the HKEX to celebrate the second…

China Probably one of the most recognisable Chinese biotechs globally, Zai Lab may only be seven years old but the company has progressed rapidly in becoming a NASDAQ-listed company with not just one but two commercial assets through a stunningly effective strategy of forming productive collaborations with the most innovative biopharma…

Hong Kong On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies have seized the opportunity to IPO under the new Chapter 18A, raising a total of over HKD 34.92 billion (USD…

China Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early drug discovery, and the next steps for the company’s expansion.   By now, we have a platform of over 500…

Roundup A roundup of the latest from Chinese pharma and biotech, including Boehringer Ingelheim’s new Shanghai R&D hub, new HKEX IPO successes for Chinese firms, further progress for Clover’s COVID-19 vaccine candidate, and more.   Boehringer creates Shanghai hub to connect with Chinese R&D groups https://www.fiercebiotech.com/biotech/boehringer-creates-shanghai-hub-to-connect-chinese-r-d-groups With China’s domestic biotech scene…

India Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials thanks to international partnerships and financial backing.    The Indian companies currently at the forefront of COVID-19 vaccine development are…